Molecular Partners Ag ADR (MOLN) Stock Price, Quote & News

Latest News on MOLN

Jan 15, 2025, 3:04 PM EST - 2 days ago

Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs

Jan 12, 2025, 1:00 PM EST - 5 days ago

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Jan 12, 2025, 1:00 PM EST - 5 days ago

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Dec 17, 2024, 4:00 PM EST - 4 weeks ago

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Dec 8, 2024, 12:00 PM EST - 5 weeks ago

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Nov 7, 2024, 4:00 PM EST - 2 months ago

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Oct 31, 2024, 4:00 PM EDT - 2 months ago

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Oct 25, 2024, 1:00 AM EDT - 3 months ago

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

Oct 22, 2024, 1:00 AM EDT - 3 months ago

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

Oct 22, 2024, 1:00 AM EDT - 3 months ago

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

Oct 4, 2024, 1:00 AM EDT - 3 months ago

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

Sep 27, 2024, 1:00 AM EDT - 4 months ago

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

Aug 26, 2024, 4:00 PM EDT - 5 months ago

Molecular Partners Reports H1 2024 Corporate Highlights and Financials

Aug 7, 2024, 5:37 AM EDT - 5 months ago

Molecular Partners: A Speculative Bet On Innovative DARPin Technology

Jun 17, 2024, 1:00 AM EDT - 7 months ago

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

Jun 14, 2024, 1:00 AM EDT - 7 months ago

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Jun 11, 2024, 1:00 AM EDT - 7 months ago

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

Jun 1, 2024, 8:00 AM EDT - 8 months ago

Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024

May 16, 2024, 4:00 PM EDT - 8 months ago

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

Apr 29, 2024, 11:00 AM EDT - 9 months ago

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Apr 19, 2024, 11:12 AM EDT - 9 months ago

Life Science Cares Launches in Switzerland

Apr 17, 2024, 11:12 AM EDT - 9 months ago

Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

Mar 26, 2024, 9:26 AM EDT - 10 months ago

Molecular Partners Publishes Invitation to Annual General Meeting 2024

Mar 15, 2024, 11:20 AM EDT - 11 months ago

Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 4:00 PM EDT - 11 months ago

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Mar 1, 2024, 4:00 PM EST - 11 months ago

Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

Jan 7, 2024, 4:00 PM EST - 1 year ago

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Jan 5, 2024, 4:00 PM EST - 1 year ago

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Dec 14, 2023, 1:00 AM EST - 1 year ago

Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

$Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting$

Dec 10, 2023, 12:00 PM EST - 1 year ago

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

Nov 14, 2023, 1:00 AM EST - 1 year ago

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

$Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition$